Key Takeaways
- Elekta raised $100.0M from EIB Group.
- Sector: Healthcare, Healthtech & Medtech.
- Geography: Sweden, Netherlands.
Analysis
Elekta, a prominent medical technology firm headquartered in Stockholm, has secured a significant financial commitment of up to €100 million from the European Investment Bank (EIB). This substantial loan is earmarked to accelerate Elekta's ambitious research and development initiatives focused on advancing treatments for oncological and neurological conditions.
The funding aligns with the EIB Group’s strategic TechEU program, designed to bolster European innovation in critical technological sectors. This infusion of capital will directly support Elekta's multi-year research program, projected to run from 2026 through 2029, with a significant portion of the work to be conducted in Sweden and the Netherlands. This initiative represents a crucial step in enhancing the competitiveness of Europe's advanced medical technology sector.
This financial backing will fuel Elekta's ongoing efforts in precision radiation medicine, encompassing radiotherapy, radiosurgery, and brachytherapy. The company's solutions are integral to treating a wide spectrum of cancers, including brain, breast, kidney, lung, pancreatic, and prostate tumors, as well as addressing neurological disorders like essential tremor and certain forms of epilepsy. Elekta's technology currently benefits over 2 million patients annually, underscoring its global impact.
The MedTech industry is experiencing robust growth, driven by an increasing demand for sophisticated healthcare solutions. Elekta's Chief Financial Officer, Klara Eiritz, highlighted the growing need for providers to manage higher patient volumes while upholding treatment quality. She stated, "This financing provides additional flexibility to support our long-term strategy and continued investments in innovation that improve clinical outcomes, operational efficiency and the patient experience." This loan will enable Elekta to further refine its adaptive radiotherapy techniques and integrated clinical workflows.
The EIB's involvement underscores a broader trend of increased investment in European HealthTech. In a comparable recent transaction, the EIB provided a €20 million venture debt agreement to Finnish digital pathology firm Aiforia in July. The European Investment Bank, a key financier for EU priorities, reported signing €100 billion in new financing across over 870 projects in 2025 alone, demonstrating its commitment to sectors like digitalization, security, and social infrastructure.
Founded in 1972 and listed on Nasdaq Stockholm, Elekta has established itself as a global leader with approximately 4,000 employees and operations in over 40 countries. The company's commitment to innovation, supported by this significant EIB loan, positions it to address the evolving challenges in cancer care and neurological treatment delivery worldwide.